Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03867435|
Recruitment Status : Recruiting
First Posted : March 8, 2019
Last Update Posted : October 18, 2019
Myotonic dystrophy is a long-term genetic disorder that affects muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and cannot relax. Researchers want to find out how various tests for DM1 or DM2 change over 2 years, to help them develop better tests for people with these diseases. Data and samples from this study will be shared with the Myotonic Dystrophy Clinical Research Network (DMCRN) investigators participating in the ongoing Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (ENDDM1) study
To find better ways to assess how myotonic dystrophy type 1 or type 2 affects people.
People ages 11 70 with DM1 or DM2
Participants will have 3 study visits over 2 years. Participants may be admitted to the clinic. Each visit may last up to a week and will include:
Medical history and physical exam
Blood, heart, and pregnancy tests
Questions about their disease
Breathing and muscle tests, including tests of movement, grip, and hand opening
Speech and swallowing exam
Magnetic resonance imaging (MRI). Participants will lie on a table that slides into a cylinder.
A magnetic field and radio waves will take pictures of the body. They may do a task during the scan. They may have a dye injected.
Pictures of chemicals in the brain or muscle taken in an MRI scanner
Thinking and memory tests
Sleep studies. Electrodes placed on the scalp will record the electrical activity of the brain.
Other devices on the body will measure heartbeat, breathing, movement, and oxygen.
Tests of electrical activity of muscles. Participants move their arms and legs with disks stuck on their skin.
Visits may also include:
Exam by a physician expert in stomach and bowel disorders
A piece of muscle and/or spinal fluid removed by needle
Sponsoring Institute: National Institute of Neurological Disorders and Stroke
|Condition or disease|
|Myotonic Dystrophy Type-1 Myotonic Dystrophy Type-2|
Objective: Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are the most common inherited skeletal myopathies in adults. RNA toxicity is the core disease mechanism, good molecular targets have been identified and there has been rapid progress in developing targeted therapies. However, incomplete characterization and limited biologic understanding of phenotypic heterogeneity, and lack of reliable clinical endpoints and biomarkers remain major obstacle in the road to therapeutic success in these diseases. The present study seeks to overcome these roadblocks building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN) (14-N-0132 study) with the following added features: 1) larger DM1 cohort including 11 - 70 year old individuals; 2) including DM2 individuals, 3) longer study duration; 4) allowing validation of NIH custombuilt devices for longitudinal measurements; and 5) including non-muscle endpoints and biomarkers specifically respiratory and central nervous system (CNS) function, which are important for survival and quality of life. The goal of the current study is to prospectively assess the disease progression over 2 years in individuals with DM1 and DM2. Selected tests, imaging and patient-reported outcomes will be assessed for ability to quantify disease burden, detect disease progression and predict changes. Additionally, we will examine muscle and cerebrospinal fluid (CSF) RNA alternative splice events as biomarkers of DM1 and DM2 severity and explore genetic modifiers of DM1 and DM2 severity by genome wide association (GWA) study.
Study population: This study plans to enroll up to 180 participants: 120 individuals with DM1 and 60 individuals with DM2 (open to both juvenile and adult individuals (11 to 70 years old, inclusive)) at the NIH Clinical Center.
Study Design: This will be a prospective observational study. No treatment will be administered as part of this study. Participants will receive standard of care as determined by their treating physician. Participants will report to the NIH Clinical Center for 3 visits each: at baseline (Visit 1), at 1-year from baseline (Visit 2), and at 2-years from baseline (Visit 3). To reduce fatigue and impact on results, each study visit be split into more than one trip to the NIH within a 30 day window) and may require the patient to be admitted to the clinical center. Each trip to the NIH for a study visit may last up to seven days. Study procedures for each visit are outlined in Section 4 and Appendix A. Data and samples will be shared with DMCRN investigators participating in Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (ENDDM1) study as indicated in Appendix B.
Outcome measures: No specific primary and secondary outcomes will be specified; however, the change in the following measures from baseline may be used to characterize the baseline status and disease progression over the course of the study: 1) muscle strength; 2) myotonia; 3) hand and upper arm functional tests; 4) measures of gait, balance and mobility; 5) skeletal muscle MRI measures of muscle mass and fatty degeneration; 6) skeletal muscle RNA biomarkers from biopsied tissue; 7) cognitive function; 8) brain MRI measures of gray matter volume, white matter hyperintensity volume, whole brain volume, integrity of white matter tracts measured as mean diffusivity and fractional anisotropy and resting state functional connectivity by functional MRI; 9) pulmonary function tests; 10) MRI measures of the diaphragm motion and contractility, myocardial function as well as myocardial fat and water composition and fibrosis; 11) clinical assessments of sleep, speech and swallow and gastrointestinal motility impairment; and 12) CSF RNA biomarkers and genetic modifiers of DM1 and DM2 severity from a GWA study in collaboration with other DMCRN researchers.
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Official Title:||Assessing Clinical Endpoint and Biomarkers in Myotonic Dystrophy Type-1 and Type-2|
|Estimated Study Start Date :||October 23, 2019|
|Estimated Primary Completion Date :||January 1, 2023|
|Estimated Study Completion Date :||January 1, 2023|
Individuals with DM1 or DM2
- to characterize baseline status and disease progression over two years in the handgrip strength by dynamometry of DM1 and DM2 patients. [ Time Frame: one year and two year ]strength of handgrip by handheld force transducer
- CSF RNA biomarkers, genetic mofiers of disease severity [ Time Frame: one and two years ]RNA splicing changes using RNA-seq in CSF and Genomewideassociation study for genetic variants predicting disease severity in collaboration with DMCRN
- muscle strength, myotonia, physical function of limbs, MRI changes of muscle fat %, cognition, brain MRI changes, diaphragm function, muscle RNA biomarkers, sleep, speech, swallow, bowel function [ Time Frame: one year and two year ]changes in the outcome measures described from baseline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03867435
|Contact: Vanessa J Ndege||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Ami K Mankodi, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|